Growth hormone secretagogues (GHS) are compounds that stimulate the pituitary gland to release endogenous growth hormone. Unlike exogenous recombinant HGH, secretagogues work upstream by modulating the natural pulsatile release mechanism, making them subjects of intense research interest in metabolic, endocrine, and longevity science.
01The GH/IGF-1 Axis
Growth hormone is released from pituitary somatotrophs under stimulation by hypothalamic growth hormone-releasing hormone (GHRH) and inhibited by somatostatin. Released GH travels to the liver and other tissues, inducing production of insulin-like growth factor 1 (IGF-1), which mediates many of GH's downstream effects including protein synthesis, lipolysis, and tissue repair signaling. Age-related decline in GH pulsatility — termed somatopause — has driven research into secretagogue-based modulation strategies.
02GHRH Analogues Under Research
GHRH analogues extend the half-life of endogenous GHRH while preserving receptor selectivity:
A modified GHRH fragment with a half-life of approximately 30 minutes. Research has documented GH pulse amplification and elevated IGF-1 in controlled investigations; its half-life and receptor kinetics are variables in laboratory study design.
The drug affinity complex (DAC) addition via lysine bonding extends half-life to approximately 8 days by exploiting albumin binding. Provides sustained GH elevation but blunts pulsatility — a consideration in research design.
03GHRPs: Ghrelin Receptor Agonists
Growth hormone releasing peptides activate the ghrelin receptor (GHS-R1a), stimulating GH release through a distinct pathway from GHRH:
A highly selective pentapeptide GHS with minimal cortisol or prolactin elevation versus other GHRPs. Published research identifies it as the 'cleanest' GHRP profile for GH-specific investigation.
A potent synthetic hexapeptide. Research shows significant GH pulse amplification but with noted cortisol and prolactin co-elevation, particularly at higher doses.
Among the first synthetic GHRPs studied. Characterized by strong ghrelin receptor activation and a pronounced appetite-stimulating effect mediated by NPY pathway engagement — an area of active obesity research.
The most potent synthetic GHRP studied. Research has additionally documented direct cardioprotective signaling via CD36 receptor binding, independent of GH release — opening cardiac research applications.
A non-peptide GHS with reported oral bioavailability. Merck research trials examined it in the context of GH deficiency, sarcopenia, and hip-fracture recovery; its pharmacokinetic profile distinguishes it from peptide comparators in the literature.
04Research Protocols & Synergy
Combining a GHRH analogue with a GHRP has been shown in research to produce synergistic GH release significantly greater than either compound alone. The combination exploits both pituitary pathways simultaneously — GHRH-R and GHS-R1a — producing amplified pulse height while maintaining physiological release architecture.
05Current Research Status
All compounds listed are classified as research chemicals. None are approved by the FDA for human use. Laboratory investigation must occur under institutional oversight with appropriate biosafety protocols. Peptide stability, reconstitution, and storage conditions significantly affect research validity.
Research Disclaimer
These compounds are sold for laboratory research use only. Not for human consumption. This article presents published scientific literature for educational purposes and does not constitute medical advice or a protocol recommendation.